Clinical trial
RADAR Trial - Randomised Androgen Deprivation and Radiotherapy
NCT00193856 · Trans Tasman Radiation Oncology Group, Other · Completed
Key facts
| NCT number | NCT00193856 |
|---|---|
| Title | RADAR Trial - Randomised Androgen Deprivation and Radiotherapy |
| Official title | A Randomised Trial Investigating the Effect on Biochemical (PSA) Control and Survival of Different Durations of Adjuvant Androgen Deprivation in Association With Definitive Radiation Treatment for Localised Carcinoma of the Prostate. |
| Lead sponsor | Trans Tasman Radiation Oncology Group, Other |
| Collaborators | National Health and Medical Research Council, Australia Hunter Medical Research Institute (HMRI) Health Research Council, New Zealand Novartis Pharmaceuticals Industry Cancer Society of New Zealand… |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug, Radiation |
| Interventions | Leuprorelin Acetate, Zoledronic Acid, Conventional external beam therapy |
| Enrollment | 1,071 |
| Start date | Oct 1, 2003 |
| Primary completion | Aug 1, 2017 |
| Completion | Aug 1, 2017 |
| First posted | Sep 19, 2005 |
| Last update posted | Oct 12, 2017 |
| Countries | Australia, New Zealand |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: